Department of Family Medicine, Qurayyat General Hospital, Al Jouf, Kingdom of Saudi Arabia.
Department of Community Medicine, Saudi Board of Family Medicine, Al Qurayyat, Kingdom of Saudi Arabia.
Hemoglobin. 2020 Nov;44(6):446-450. doi: 10.1080/03630269.2020.1853561. Epub 2021 Jan 12.
Thalassemia is a genetic mutation of the α- or β-globin chains that lead to defective erythropoiesis. This study aimed to collect evidences from all published studies that investigated the clinical effectiveness of calcium channel blockers (CCBs) in conjunction with chelation therapy for reducing iron overload in patients with thalassemia. A systematic search was conducted in PubMed, Institute for Scientific Information (ISI) Web of Science, Scopus, Cochrane Central Register of Controlled Trials, and Virtual Health Library. Original studies reporting the use of CCBs in patients with thalassemia were included for meta-analysis. A total of five randomized studies including 210 patients were included with a follow-up period of 3-12 months. There was no significant difference between amlodipine and control groups in increasing the heart T2* magnetic resonance imaging (MRI) [mean difference (MD) 95% confidence interval (95% CI) = -1.9 (-4.4 to 0.5), = 0.119] or reducing the liver iron concentration [MD 95% CI = -0.046 (-0.325 to 0.2), = 0.746]. Although there were no serious adverse events reported in the included trials, further studies are recommended to strengthen our findings.
地中海贫血是α-或β-球蛋白链的基因突变，导致红细胞生成缺陷。本研究旨在收集所有已发表的研究证据，这些研究调查了钙通道阻滞剂 (CCB) 与螯合疗法联合用于减少地中海贫血患者铁过载的临床效果。在 PubMed、科学信息研究所 (ISI) Web of Science、Scopus、Cochrane 对照试验中心注册库和虚拟健康图书馆中进行了系统搜索。纳入了报告使用 CCB 治疗地中海贫血患者的原始研究进行荟萃分析。共有 5 项随机研究纳入了 210 例患者，随访时间为 3-12 个月。氨氯地平组与对照组在增加心脏 T2*磁共振成像 (MRI) [平均差异 (MD) 95%置信区间 (95%CI) = -1.9 (-4.4 至 0.5)， = 0.119]或降低肝脏铁浓度 [MD 95%CI = -0.046 (-0.325 至 0.2)， = 0.746]方面无显著差异。尽管纳入的试验中没有报告严重不良事件，但建议进行进一步的研究来加强我们的发现。
